All Releases
|
Safety and Tolerability of Dimebon for up to 26 Weeks in Patients with Mild-to-Moderate Alzheimer's Disease
Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) 2010
Jul 14, 2010 |
 205.4 KB |
|
|
|
American Society of Clinical Oncology (ASCO) Annual Meeting
Circulating Tumor Cells and Prostate-Specific Antigen as Response Indicator Biomarkers in Chemotherapy-Naive Patients with Progressive Castration-Resistant Prostate Cancer Treated with MDV3100
Jun 7, 2010 |
164.0 KB |
|
|
Medivation Reports First Quarter 2010 Financial Results and Provides Corporate Update
May 10, 2010 |
20.3 KB |
|
| |
SAN FRANCISCO, May 10, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2010.
"After thorough review of all available dimebon data, including the disappointing CONNECTION results, Medivation remains committed to d...
|
|
|
Medivation Announces First Quarter 2010 Financial Results Teleconference and Webcast on May 10, 2010
May 3, 2010 |
7.6 KB |
|
| |
SAN FRANCISCO, May 3, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss first quarter 2010 financial results and provide a general business update on May 10, 2010, at 4:30 p.m. Eastern Time. A press release for the first quarter ende...
|
|
|
American Academy of Neurology (AAN) Annual Meeting
Latrepirdine is Well-Tolerated in Patients with Alzhimer's Disease Receiving Memantine or Memantine Plus Donepezil
Apr 14, 2010 |
62.6 KB |
|
|
|
American Academy of Neurology (AAN) Annual Meeting
Cognition Enhancement by Dimebon (Latrepirdine) is Not Mediated by Acetylcholinesterase Inhibition or NMDA Receptor Modulation
Apr 14, 2010 |
91.0 KB |
|
|
|
American Academy of Neurology (AAN) Annual Meeting
Dimebon (Latrepirdine) Stimulates Neurite Outgrowth and Protects Against Mitochondrial Depolarization in Cultured Hippocampal Neurons
Apr 14, 2010 |
185.2 KB |
|
|
|
Medivation And Astellas Announce Publication In The Lancet Of Positive Efficacy Data From Phase 1-2 Trial Of MDV3100 In Advanced Prostate Cancer Patients
Apr 14, 2010 |
16.5 KB |
|
| |
SAN FRANCISCO, CA and TOKYO, JAPAN -- April 14, 2010 -- Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced publication of positive results from their previously reported Phase 1-2 trial of the novel triple-acting oral androgen receptor antagonist MDV3100 in men with progressive, metastatic castration-resistant pros...
|
|
|
Medivation Announces Reduction in Workforce
Mar 29, 2010 |
10.1 KB |
|
| |
SAN FRANCISCO, March 29, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that the Company is implementing a plan to reduce its workforce and operating costs in order to focus its resources on prioritized dimebon trials and the continued development of MDV3100. The Company will reduce the number of staf...
|
|
|
American Society for Critical Pharmacology and Therapeutics (ASCPT)
Lack of a Pharmacokinetic Interaction between Dimebon (Latrepirdine) and Digoxin in Healthy Subjects
Mar 20, 2010 |
746.2 KB |
|
|
|
American Society for Critical Pharmacology and Therapeutics (ASCPT)
Lack of a Pharmacokinetic and Pharmacodynamic Interaction between Dimebon (Latrepirdine) and Warfarin in Healthy Subjects
Mar 19, 2010 |
769.1 KB |
|
|
|
Medivation Reports Fourth Quarter and Year-End 2009 Financial Results and Provides Corporate Update
Mar 15, 2010 |
19.7 KB |
|
| |
SAN FRANCISCO, March 15, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the year ended December 31, 2009.
"We are disappointed by the results of the Phase 3 CONNECTION trial in Alzheimer's patients, and it is our highest priority to work with ou...
|
|
|
Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010
Mar 12, 2010 |
7.8 KB |
|
| |
SAN FRANCISCO, March 12, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss fourth quarter and year-end 2009 financial results and provide a general business update on March 15, 2010, at 4:30 p.m. Eastern Time. A press release for the...
|
|
|
American Society of Clinical Oncology Genitourinary Cancer Symposium
Circulating Tumor Cells and Prostate-Specific Antigen as Response Indicator Biomarkers in Patients With Progressive Castration-Resistant Prostate Cancer Treated With MDV3100
Mar 6, 2010 |
168.6 KB |
|
|
|
American Association for Geriatric Psychiatry (AAGP)
Latrepirdine is Well-Tolerated in Patients With Alzheimer's Disease Receiving Memantine or Memantine Plus Donepezil
Mar 5, 2010 |
95.3 KB |
|
|
|
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Mar 3, 2010 |
18.0 KB |
|
| |
NEW YORK & SAN FRANCISCO, Mar 03, 2010 (BUSINESS WIRE) -- Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today
announced results from two Phase 3 trials of the investigational
drug dimebon (latrepirdine*) in patients with Alzheimer's disease (AD).
In the CONNECTION trial, dimebon did not meet its co-primary or
...
|
|
|
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease
Mar 2, 2010 |
7.3 KB |
|
| |
SAN FRANCISCO, March 2, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Wednesday, March 3, to discuss Phase 3 trial results for dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's Disease. A press releas...
|
|
|
Medivation Announces Participation in Upcoming Conferences
Mar 1, 2010 |
7.3 KB |
|
| |
SAN FRANCISCO, March 1, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:
The Cowen Healthcare Conference, Monday, March 8, at 4:45 p.m. Eastern Time at the Marriott Copley Place Hotel in BostonThe ROT...
|
|
|
Medivation Announces Participation in 12th Annual BIO CEO & Investor Conference
Feb 2, 2010 |
7.7 KB |
|
| |
SAN FRANCISCO, Feb 02, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will be a featured speaker on a panel entitled, "Alzheimer's Disease: A Panel To Remember," at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, at 9:0...
|
|
|
Medivation Announces European Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Jan 12, 2010 |
13.2 KB |
|
| |
SAN FRANCISCO, January 12 /PRNewswire/ -- Medivation, Inc. today announced treatment of the first European patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. The trial, known as AFFIRM, will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who ...
|
|
|
